LIDDS’s Annual Report 2021 Published

Regulatory

Uppsala, 26 April, 2022 – The 2021 Annual report of LIDDS AB (publ) is now available on the company website.

The annual report is available in PDF format on the company website at: https://liddspharma.com/en/investors/financial-reports/

Printed copies can be ordered from LIDDS AB, Virdings allé 32B, SE- 754 50 Uppsala, or by e-mail: info@liddspharma.com

For additional information, please contact

Nina Herne, CEO
Phone: +46 (0)70 714 74 57
E-mail: nina.herne@liddspharma.com
 
Jenni Björnulfson, CFO
Phone: +46 (0)708 55 38 05
E-mail: jenni.bjornulfson@liddspharma.com

LIDDS’ Certified Adviser is Redeye AB
Tel: [+46] 8 121 576 90
E-mail: certifiedadviser@redeye.se

LIDDS in brief:

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and solve problems within many indication areas. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage development, and projects about to enter clinical phase. The company is listed on Nasdaq First North Growth market.

Attachments

LIDDS Årsredovisning 2021 FINAL